Von Hippel–Lindau (VHL) Disease

VHL disease is an inherited condition that makes a person more likely to develop certain tumors and cysts in different parts of the body. These growths can be non-cancerous or cancerous, and they most often appear in the eyes (retina), brain and spinal cord, kidneys, pancreas, inner ear, adrenal glands, and the male epididymis or female broad ligament. VHL is passed down in families in an autosomal dominant way, which means a person usually needs just one altered copy of the VHL gene to have the condition, and each child has a 50% chance to inherit it. The single root cause is a harmful change in the VHL gene, but different people in the same family can still have different patterns of tumors and symptoms, and problems can happen at different ages. Cancer.govMedlinePlusNCBIrarediseases.info.nih.gov

Von Hippel–Lindau disease (VHL) is a rare, inherited condition that raises the chance of developing multiple tumors and cysts across the body—especially in the eyes (retina), brain and spinal cord (hemangioblastomas), kidneys (clear-cell renal cell carcinoma and cysts), pancreas (cysts and neuroendocrine tumors), inner ear (endolymphatic sac tumors), and adrenal glands (pheochromocytoma). It happens because a change (pathogenic variant) in the VHL tumor-suppressor gene makes the cell’s oxygen-sensing system overactive. The VHL protein normally tags “HIF” proteins for clean-up; when VHL is faulty, HIF builds up, driving abnormal blood-vessel growth and tumors. VHL is autosomal dominant, so each child of an affected parent has a 50% chance to inherit it. Most people who carry a disease-causing VHL variant eventually develop one or more VHL-related growths by later adulthood, which is why lifelong surveillance is essential. Cancer.govPMCScienceDirect

Your cells constantly “sense oxygen.” The VHL protein is part of this oxygen-sensing system. In healthy cells, VHL helps remove a signal protein called HIF (hypoxia-inducible factor) when oxygen is normal, so blood-vessel growth signals stay balanced. When the VHL gene is damaged, the VHL protein cannot control HIF correctly. HIF then builds up and turns on many genes that make blood vessels grow, encourage cell survival, and change cell metabolism. Over time, this overactive signaling makes vascular tumors like hemangioblastomas and raises the risk of clear-cell kidney cancer and other VHL-related tumors. In short, a broken VHL gene lets HIF run too high for too long, and that steady push helps tumors form and grow. JCIPMCPubMed

Types

Doctors often describe VHL by clinical subtypes, because some families mainly get certain tumors while others get different ones. These “types” are based on what shows up most often in that family, and they can help guide screening. The names vary across sources, but the core idea is the same: some groups have low risk of pheochromocytoma (an adrenal gland tumor) and others have high risk. Mosaic VHL (where only some cells carry the gene change) can also occur. Here’s a simple map:

1. Type 1 VHL – People are prone to hemangioblastomas in the brain, spine, and retina, plus kidney cysts and clear-cell renal cell carcinoma (RCC), pancreatic cysts and sometimes pancreatic neuroendocrine tumors. The risk of pheochromocytoma is low in this group. Cancer.gov

2. Type 2A VHL – People have a high risk of pheochromocytoma and hemangioblastomas, but a lower risk of RCC compared with Type 2B. Cancer.gov

3. Type 2B VHL – People have a high risk of pheochromocytoma and a high risk of RCC, along with hemangioblastomas. This subtype needs especially careful kidney surveillance. Cancer.gov

4. Type 2C VHL – People mostly present with pheochromocytoma without other typical VHL tumor types, so the disease may be suspected from adrenal symptoms first. Cancer.gov

5. Mosaic VHL – Only a portion of the body’s cells carry the VHL change, often from a new change that happened early in development, so the pattern of tumors can be patchy and sometimes milder or later, and genetic testing may need special methods to detect the mosaic change. Cancer.gov

Causes

Plain-language note: there is one true root cause of VHL disease—a harmful germline change in the VHL gene. The list below expands that single root cause into 20 practical “drivers” that explain why people develop different tumors, why tumors appear at different ages, and how the VHL defect triggers disease in the body. These items include types of VHL gene changes, cell-level steps, and modifiers that shape severity over a lifetime.

1. Germline VHL gene pathogenic variant – An inherited harmful change in one VHL copy is the basic cause that sets lifetime risk. Cancer.gov

2. Missense variants – A single-letter DNA change that alters one amino acid can weaken VHL protein function and is common in families with Type 2 patterns. Cancer.gov

3. Truncating variants (nonsense/frameshift) – These changes cut the protein short, often causing strong loss of function and are common in Type 1 families. Cancer.gov

4. Splice-site variants – Changes at intron–exon borders can disrupt how the gene is read, reducing normal VHL protein. Cancer.gov

5. Large deletions/duplications – Missing or extra chunks of the VHL gene can remove its function. Cancer.gov

6. De novo variants – A new VHL change can occur in a child even if parents test negative, starting VHL in that family line. Cancer.gov

7. Mosaicism – If the new change happens after the first cell divisions, only some tissues carry VHL change, which can alter where and when tumors appear. Cancer.gov

8. Second-hit loss in tumors – Tumors usually form when the remaining healthy VHL copy in a cell is lost or silenced, completing the “two-hit” path to tumor growth. JCI

9. HIF-alpha stabilization – Without working VHL protein, HIF is not broken down, so it stays switched on and drives abnormal growth programs. JCIPMC

10. VEGF and angiogenesis overdrive – HIF triggers blood-vessel growth signals like VEGF, making vascular tumors such as hemangioblastomas more likely. JCI

11. Metabolic reprogramming – HIF pushes cells toward glycolysis and other changes that help tumor cells survive low oxygen and grow. PMC

12. Tissue-specific vulnerability – Some organs (retina, cerebellum, kidneys, inner ear) are more sensitive to HIF overactivity, which is why VHL “targets” these sites. Cancer.gov

13. Genotype–phenotype correlations – Certain VHL variant types are linked with higher pheochromocytoma risk, while others lean toward kidney cancer risk. Cancer.gov

14. Age-related penetrance – Risk accumulates with age, so more tumors are seen as people get older, even within the same family. NCBI

15. Epigenetic/other genetic modifiers – Background genes and epigenetic changes can modulate how strongly VHL loss drives tumors, helping explain variable severity. (Inference consistent with reviews on VHL/HIF biology.) JCIPMC

16. Local tissue hypoxia – Areas with intermittent low oxygen may exaggerate HIF signals in VHL-deficient cells and promote growth. (Mechanistic inference from oxygen-sensing pathway literature.) PMC

17. Inflammatory microenvironment – HIF signaling can interact with inflammation, which may support tumor blood-vessel formation and survival. (Biology review inference.) ATS Journals

18. Hormonal stress in adrenal medulla – In people predisposed to pheochromocytoma, adrenal cells with VHL loss respond abnormally to stress signals. (Mechanism aligned with VHL–pheochromocytoma literature.) Cancer.gov

19. Cyst formation pathways – VHL loss can disturb normal tubule and duct biology in kidneys and pancreas, making cysts more likely. Cancer.gov

20. Chance (stochastic events) – Even with the same VHL variant, random events in when and where the second hit occurs change who gets which tumors first. (Concept from two-hit tumor-suppressor biology.) JCI

Common symptoms

Symptoms vary widely. Some people feel well for years and only find tumors on screening. Others notice symptoms early. Always tell a clinician about new or worsening symptoms.

1. Vision changes – Blurred or distorted sight, new floaters, or loss of part of the visual field can occur when retinal hemangioblastomas leak fluid or bleed.

2. Eye redness or pain – Less common but can happen if the retinal lesion or treatment causes inflammation or pressure changes.

3. Headaches – Steady or worsening headaches can be caused by brain hemangioblastomas increasing pressure inside the skull.

4. Balance problems – Tumors in the cerebellum can cause unsteady walking, clumsiness, or trouble coordinating hand movements.

5. Neck or back pain – Spinal hemangioblastomas can cause aching pain that may spread, especially if the tumor irritates nerves.

6. Numbness or weakness – A spinal lesion pressing on nerves can cause numbness, tingling, or weakness in the arms or legs.

7. Hearing loss – A slow-worsening loss of hearing in one ear can be a sign of an endolymphatic sac tumor of the inner ear.

8. Ringing in the ear (tinnitus) – A steady noise in one ear can accompany inner ear tumors.

9. Sudden vertigo – Brief, spinning dizziness or imbalance may happen when inner ear pressure changes.

10. High blood pressure – Pheochromocytoma can push blood pressure very high, sometimes in sudden spikes.

11. Pounding heart, sweating, and headaches in spells – These “adrenaline-like” attacks are classic pheochromocytoma signs.

12. Blood in the urine – Clear-cell RCC or kidney cysts can bleed and cause pink or red urine.

13. Side or belly pain – Kidney or pancreatic cysts or tumors can cause dull or sharp pain in the flank or abdomen.

14. Early satiety or weight changes – Pancreatic neuroendocrine tumors or large cysts can press on stomach structures and change appetite.

15. Fertility or scrotal swelling issues – Epididymal cystadenomas in men can cause a painless scrotal mass or fertility concerns; women can develop broad-ligament cystadenomas that cause pelvic pressure. Cancer.gov

Diagnostic tests

Doctors choose tests based on age, family history, symptoms, and screening guidelines. People with a known VHL variant usually follow a lifelong surveillance plan with regular exams and imaging to find small tumors early, when treatment is easier and safer. PubMedACS JournalsVHL Alliance

A) Physical exam

1. Blood pressure measurement (sitting and sometimes standing) – Very high or variable readings can suggest a pheochromocytoma that is releasing catecholamines; repeated checks help confirm the pattern.

2. Focused neurologic exam – A clinician checks eye movements, speech, balance, strength, and sensation; any focal change can point toward a brain or spinal lesion needing MRI.

3. Gait and coordination tests – Simple bedside tests like heel-to-toe walking or finger-to-nose can show cerebellar problems that raise suspicion for hemangioblastoma.

4. Abdominal exam – Gentle pressing and listening can reveal tenderness, masses, or organ enlargement that may reflect kidney or pancreatic cysts/tumors.

5. Ear and hearing-focused head & neck exam – Inspection of the ear and cranial nerves helps spot clues to endolymphatic sac tumors.

B) Manual/bedside tests

6. Indirect ophthalmoscopy (dilated fundus exam) – An eye specialist looks directly at the back of the eye to find retinal hemangioblastomas early, even before vision changes.

7. Slit-lamp biomicroscopy with scleral depression (as needed) – A magnified light exam helps map small peripheral retinal lesions and plan treatment.

8. Tuning fork tests (Rinne and Weber) – Simple bedside hearing checks can quickly suggest a conductive vs. sensorineural pattern, guiding inner-ear imaging.

9. 24-hour or home blood-pressure logs – Manual or automated frequent readings can unmask paroxysmal hypertension spells suggestive of pheochromocytoma.

C) Laboratory & pathology

10. Plasma free metanephrines – A very sensitive blood test for breakdown products of adrenaline and noradrenaline; elevated values strongly suggest pheochromocytoma and lead to confirmatory imaging.

11. 24-hour urine fractionated metanephrines and catecholamines – A complementary test that catches episodic surges when blood levels vary, improving diagnostic confidence.

12. Germline VHL genetic testing (sequencing + deletion/duplication analysis) – Confirms the diagnosis, allows testing of relatives, and guides lifelong surveillance.

13. Tumor pathology (if surgery is done) – Examining removed tissue under the microscope confirms the tumor type (e.g., clear-cell RCC, hemangioblastoma) and helps plan follow-up.

14. Basic kidney function labs and urinalysis – Creatinine, eGFR, and urine checks help monitor kidney health and look for blood in urine from RCC or cysts.

15. Hormone markers for pancreatic neuroendocrine tumors (as indicated) – Tests such as chromogranin A or specific peptide hormones may be used when pNET is suspected. Cancer.gov

D) Electrodiagnostic

16. Electrocardiogram (ECG) – High adrenaline from pheochromocytoma can trigger heart rhythm changes; ECG provides a quick safety check if palpitations or chest symptoms occur.

17. Auditory brainstem response (ABR) – An objective hearing test that measures how sound signals travel from the ear to the brainstem; it can support evaluation for endolymphatic sac tumors when standard hearing tests are difficult.

E) Imaging

18. MRI of brain and spine with contrast – The main imaging test to find hemangioblastomas early, track growth, and plan surgery or other treatments while preserving function.

19. Dilated fundus photography and fluorescein angiography – Detailed eye images and dye testing show very small retinal lesions and leakage, guiding laser or other eye treatments.

20. Optical coherence tomography (OCT) – A non-invasive eye scan that shows retinal layers in microscopic detail, helping detect macular edema from retinal tumors early.

21. MRI of the internal auditory canal/temporal bone – Focused inner-ear MRI looks for endolymphatic sac tumors in people with hearing loss, tinnitus, or vertigo.

22. MRI (or CT) of the abdomen – Periodic imaging of kidneys, pancreas, and adrenal glands looks for RCC, cysts, pancreatic NETs, and pheochromocytoma.

23. Ultrasound (kidney and abdomen) – A radiation-free way to watch cysts and screen between MRIs; useful for children and during interim follow-up.

24. Functional imaging for pheochromocytoma/paraganglioma – Depending on availability, MIBG scintigraphy, 18F-FDOPA PET, or 68Ga-DOTATATE PET/CT can localize adrenal or extra-adrenal disease when biochemical tests are positive. Cancer.govPubMed

Non-pharmacological treatments (therapies & others)

1) Lifelong, structured surveillance program.
What it is: A standing plan that schedules regular eye exams, brain/spine MRI, abdominal MRI/ultrasound, blood pressure checks, and labs—tailored by age and personal/family history.
Purpose: Find tumors early while they’re small and easier to treat; avoid emergencies.
How it works: Evidence-based intervals reduce morbidity by catching silent growths before they cause damage. PubMedVHL Alliance

2) Annual (or more frequent) dilated eye exams by a retina specialist.
Purpose: Detect small retinal hemangioblastomas before they leak fluid or bleed.
How it works: Careful exam and imaging guide timely laser or cryotherapy to preserve sight. AAOEyeWiki

3) Periodic brain and spinal MRI with contrast.
Purpose: Track CNS hemangioblastomas and plan neurosurgical or radiosurgical care before neurological injury occurs.
How it works: MRI reveals size and cystic change; timing is chosen to intervene before symptoms worsen. PubMed

4) Abdominal MRI (preferred over repeated CT).
Purpose: Watch kidneys and pancreas while minimizing lifetime radiation.
How it works: MRI detects small clear-cell RCCs and pancreatic NETs; the classic “3-cm rule” often guides timing of kidney surgery. American Urological AssociationPMC

5) Genetic counseling & cascade testing for relatives.
Purpose: Identify at-risk family members early so surveillance can start before problems appear.
How it works: A blood/saliva test confirms the family’s VHL variant; first-degree relatives can be tested from childhood with age-appropriate surveillance. Cancer.gov

6) Pre-pregnancy and pregnancy planning.
Purpose: Lower risks during pregnancy; choose safer timing for surgeries/meds.
How it works: Multidisciplinary counseling (obstetrics, genetics, ophthalmology, neurosurgery, urology, endocrinology) adjusts surveillance and treatment around pregnancy.

7) Blood pressure self-monitoring.
Purpose: Spot pheochromocytoma early (spells of severe headaches, palpitations, sweating, and high BP).
How it works: Home BP logs prompt targeted biochemical testing and timely adrenal surgery. NCBI

8) Hearing and balance monitoring (audiology & ENT).
Purpose: Detect endolymphatic sac tumors (ELST) early to preserve hearing.
How it works: Audiograms and inner-ear MRI trigger timely ear surgery. Thieme

9) Retinal laser photocoagulation.
Purpose: Seal tiny retinal hemangioblastomas to stop leakage and protect central vision.
How it works: Focused light “spot-welds” the feeder vessels; best for small, posterior lesions. VHL Alliance

10) Retinal cryotherapy.
Purpose: Treat small-to-medium peripheral lesions when laser is less effective.
How it works: A freezing probe closes tumor vessels to stop exudation and detachments. VHL Alliance

11) Photodynamic therapy (select centers).
Purpose: Alternative for certain small/medium retinal tumors.
How it works: Light-activated drug generates local free radicals that collapse abnormal vessels. Bryn Mawr Communications

12) Stereotactic radiosurgery (SRS) for CNS hemangioblastomas (e.g., Gamma Knife).
Purpose: Control small or surgically challenging brain lesions with pinpoint radiation.
How it works: Sub-millimeter targeting delivers high dose to the tumor while sparing normal brain; long-term series show high local control. Oxford AcademicPubMed

13) Pre-operative spinal/cranial tumor embolization (selected cases).
Purpose: Reduce bleeding risk in highly vascular hemangioblastomas before surgery.
How it works: Interventional radiology temporarily blocks feeding arteries; used selectively due to mixed evidence. PMCSpringerLink

14) Thermal ablation for small kidney tumors (experienced centers).
Purpose: Treat small RCCs while preserving kidney tissue when surgery is high-risk.
How it works: Needle-guided radiofrequency or cryoablation destroys tumor with heat/cold. PMC

15) Low-vision rehabilitation (if vision is impaired).
Purpose: Maximize independence when retinal damage limits sight.
How it works: Training, magnifiers, electronic aids, and orientation/mobility instruction.

16) Post-operative neuro-rehabilitation.
Purpose: Restore balance, strength, and fine motor skills after brain/spine surgery.
How it works: Physical and occupational therapy re-train movement patterns and prevent falls.

17) Individualized activity guidance.
Purpose: Avoid falls, barotrauma, and pressure spikes that could worsen symptoms.
How it works: Your team may advise pausing contact sports, heavy straining, or scuba diving around eye or brain procedures.

18) Smoking cessation and alcohol moderation.
Purpose: Protect kidney function and surgical healing; lower vascular and BP risks.
How it works: Counseling, nicotine-replacement, and support programs improve success.

19) Mental-health and peer-support care.
Purpose: Reduce anxiety, grief, and stress that can accompany lifelong surveillance.
How it works: Counseling, support groups, and the VHL Alliance resources help families cope. VHL Alliance

20) Travel and altitude planning during belzutifan.
Purpose: Lower risk of hypoxia (low oxygen) while on HIF-2α inhibitor therapy.
How it works: Check pulse oximetry, plan for supplemental oxygen if needed, and avoid high-altitude trips until your team says it’s safe. FDA Access Data

---

Drug treatments

Safety first: Drug choices depend on which VHL manifestation you have (kidney, CNS, retina, pancreas, adrenal, inner ear), your age, other illnesses, and current scans/labs. Doses below are typical adult starting regimens; your clinician will individualize. Always confirm details with your specialist.

1) Belzutifan (WELIREG) — HIF-2α inhibitor.
Class & purpose: Targeted therapy that directly blocks HIF-2α, the key oxygen-sensing driver in VHL tumors; used in adults with VHL who need treatment for RCC, CNS hemangioblastoma, or pancreatic NET not requiring immediate surgery.
Dose & time: 120 mg by mouth once daily, continued until progression or unacceptable toxicity.
Mechanism: Lowers HIF-2α activity → reduces pro-angiogenic signaling (like VEGF).
Common side effects: Anemia, hypoxia, fatigue, headache, creatinine rise; embryo-fetal toxicity—strict contraception required.
Notes: Monitor hemoglobin and oxygen saturation regularly; dose adjustments for toxicities. FDA Access Data

2) Sunitinib — VEGF-TKI (for metastatic/progressive RCC).
Dose: Commonly 50 mg daily, 4 weeks on/2 weeks off (or 37.5 mg continuous).
Mechanism: Inhibits VEGF and other kinases to starve tumors of blood supply.
Side effects: Fatigue, hypertension, hand-foot syndrome, diarrhea; thyroid and BP monitoring required. Cloudfront

3) Pazopanib — VEGF-TKI (for RCC).
Dose: 800 mg daily.
Mechanism & purpose: Similar anti-angiogenic action; sometimes better tolerated in certain patients.
Side effects: Liver enzyme elevation, hypertension, diarrhea; routine LFTs. Cloudfront

4) Everolimus — mTOR inhibitor (for pancreatic NET).
Dose: 10 mg daily.
Purpose: Slows growth of VHL-associated pancreatic neuroendocrine tumors.
Side effects: Mouth sores, high blood sugar, infection risk; monitor glucose and lipids. nanets.net

5) Octreotide LAR — somatostatin analog (functional/non-functioning pNET).
Dose: 20–30 mg IM every 4 weeks (individualize).
Purpose: Controls hormone-related symptoms; may slow tumor growth.
Side effects: Gallstones, steatorrhea, glucose shifts. nanets.net

6) Lanreotide depot — somatostatin analog (pNET).
Dose: 120 mg deep SC every 4 weeks.
Mechanism & effects: As above; choose based on availability/tolerance. nanets.net

7) Phenoxybenzamine — nonselective α-blocker (pheochromocytoma, pre-op).
Dose: Often starts 10 mg twice daily, titrated up over days to weeks.
Purpose: Blocks catecholamine effects to make adrenal surgery safer.
Side effects: Orthostatic dizziness, nasal stuffiness, fatigue. Oxford AcademicMayo Clinic

8) Doxazosin — selective α1-blocker (pheochromocytoma, pre-op).
Dose: Often 1 mg daily, increased gradually; sometimes held the night before surgery.
Purpose & mechanism: Smooth muscle relaxation → better BP control and volume expansion.
Side effects: Dizziness, fatigue; less reflex tachycardia than phenoxybenzamine. Oxford Academic

9) Propranolol (or other β-blocker) — only after α-blockade is established.
Dose: Commonly 10–40 mg three times daily, titrated to heart rate.
Purpose: Controls tachycardia from catecholamines or α-blocker.
Warning: Never start β-blocker first; it can trigger dangerous BP spikes. Mayo Clinic

10) Metyrosine — catecholamine synthesis inhibitor (adjunct for pheochromocytoma).
Dose: Often 250 mg four times daily, titrated as needed.
Purpose: Lowers catecholamine production when BP remains hard to control.
Side effects: Sedation, depression, extrapyramidal symptoms; used by experienced teams. NCBI

---

Dietary, “molecular” supplements

Important: No supplement treats or cures VHL. Use these only to support general health, surgery recovery, and energy—and only with your clinicians, especially if you are on belzutifan or other cancer medicines (drug–supplement interactions are possible).

1. Vitamin D3 (cholecalciferol), 1000–2000 IU/day with food. Supports bone and muscle health during periods of reduced activity or steroid use.

2. Omega-3 fatty acids (EPA+DHA), ~1 g/day. Supports triglycerides and may ease inflammation; stop before surgeries if your surgeon requests.

3. Calcium (diet first; supplement to ~1000 mg/day total) if intake is low—bone support, especially if on steroids or after prolonged immobility.

4. B-complex with B12 (e.g., 500–1000 mcg/day if low) for energy and neuropathy protection if you develop deficiencies.

5. Folate (400 mcg/day) from diet or supplement if low; essential for cell turnover—avoid in pregnancy unless your OB sets the dose.

6. Magnesium glycinate (200–400 mg/day) for cramps, sleep, and bowel regularity if constipation is a problem.

7. Lutein + zeaxanthin (10 mg/2 mg/day) for general retinal nutrition; not a VHL therapy but safe for eye health.

8. Coenzyme Q10 (100–200 mg/day) for fatigue in some patients; discuss if you take blood thinners.

9. Probiotic foods or a daily probiotic for bowel regularity during stress, travel, or post-op periods.

10. Curcumin (500–1000 mg/day with piperine cautiously) for aches; avoid if you have bleeding risk or upcoming surgery; possible interactions with drug metabolism.

Tip: Keep a single updated list of all supplements and share it with every clinician and pharmacist.

---

Regenerative / stem-cell” drug ideas — what’s real

Important safety note: There are no approved “hard immunity booster,” regenerative, or stem-cell drugs for VHL. Stem-cell therapies for VHL-related tumors are investigational only. If you see clinics offering “stem cells to cure VHL,” treat that as a red flag. Below are research directions your team might discuss only in clinical trials:

1. Gene therapy to correct VHL (e.g., viral vectors delivering healthy VHL): laboratory/early translational stage.

2. CRISPR-based gene editing of VHL-mutant cells: preclinical; not available clinically for VHL today.

3. Induced pluripotent stem-cell (iPSC) retinal support for end-stage retinal damage: experimental in other diseases; not established in VHL.

4. Inner-ear hair-cell regeneration concepts for ELST-related hearing loss: experimental; currently surgery is standard. SpringerLink

5. Cancer vaccines / adoptive immune therapies: explored broadly in RCC; not specific to non-metastatic VHL care.

6. Combination HIF-2α targeting with other pathways (e.g., mTOR/VEGF) in trials to delay surgery further.

Best practice today: Discuss clinicaltrials.gov options with your VHL team and do not start unregulated “stem-cell” treatments.

---

Surgeries

1) Nephron-sparing partial nephrectomy (kidney).
Procedure: Robotic or open removal of just the kidney tumor with a thin margin, preserving healthy kidney.
Why: Clear-cell RCC in VHL often occurs multiple times; preserving kidney tissue lowers the chance of dialysis. Many centers intervene when the largest renal tumor reaches ~3 cm. American Urological Association

2) Microsurgical resection of CNS hemangioblastoma.
Procedure: Precise removal of the tumor (often with the cyst) using microsurgical tools; sometimes preceded by selective embolization.
Why: Relieves pressure, prevents progressive neurological deficit; surgery is curative for many solid lesions. PMC

3) Stereotactic radiosurgery (Gamma Knife/CyberKnife) for small brain lesions.
Procedure: One or a few sessions of focused beams; no incision.
Why: High local control for surgically risky or multiple lesions; can delay or avoid craniotomy. Oxford Academic

4) Adrenal-sparing laparoscopic surgery for pheochromocytoma.
Procedure: Removal of the tumor while preserving adrenal cortex when safe; requires pre-op α-blockade ± β-blocker.
Why: Controls life-threatening catecholamine surges and preserves adrenal hormones. NCBI

5) Parenchyma-sparing pancreatic surgery (e.g., enucleation or limited pancreatectomy).
Procedure: Remove only the tumor when it is small and away from the main pancreatic duct; larger or risky tumors get formal resection.
Why: Treat pancreatic NETs while avoiding diabetes and exocrine insufficiency whenever possible. PMC

---

Preventions

1. Stick to a formal surveillance calendar. It’s the single most powerful “prevention” tool in VHL. PubMed

2. Manage blood pressure and seek testing for catecholamine excess if you have spells. NCBI

3. Prefer MRI over repeated CT to limit lifetime radiation. PubMed

4. Operate at experienced centers that know VHL; outcomes and kidney preservation are better. PMC

5. Protect kidney function (hydrate, avoid unnecessary NSAIDs, avoid smoking).

6. Tell anesthesiologists about possible pheochromocytoma before any procedure. NCBI

7. Follow eye safety (prompt care for floaters/flashes; protect eyes from trauma). PMC

8. Plan pregnancy with your VHL team; review meds like belzutifan (pregnancy risk). FDA Access Data

9. Vaccinate and prevent infections to avoid delays around surgeries or MRIs.

10. If on belzutifan, watch for hypoxia—monitor pulse oximetry during illness and travel; ask about altitude. FDA Access Data

---

When to see doctors urgently

• New or worsening vision symptoms: sudden floaters, flashes, blurring, a dark curtain, or eye pain.

• Neurologic warning signs: severe headache, vomiting, double vision, new imbalance, limb weakness, numbness, or sudden bladder/bowel issues.

• Spells of high blood pressure with pounding heartbeat, sweating, pallor, tremor, or chest pain—especially if paroxysmal.

• Blood in urine, new flank pain, or rapidly increasing abdominal girth.

• New hearing loss, roaring tinnitus, or vertigo—possible ELST.

• If on belzutifan: unusual shortness of breath, dizziness, extreme fatigue, or low finger-oximeter readings. NINDSFDA Access Data

---

What to eat” and “what to avoid”

1. Eat: plenty of vegetables, fruits, legumes, whole grains, and lean proteins to support recovery and energy. Avoid: ultra-processed foods high in sodium that worsen BP.

2. Eat: adequate protein at each meal (fish, eggs, beans, poultry) during post-op periods. Avoid: crash diets that impair healing.

3. Drink: regular water intake unless on fluid restriction. Avoid: chronic dehydration that stresses kidneys.

4. Eat: fiber-rich foods for bowel regularity (oats, beans, berries). Avoid: excess added sugars that worsen fatigue and weight.

5. Use: healthy fats (olive oil, nuts). Avoid: trans fats.

6. Consider: calcium and vitamin D via diet; ask before supplementing. Avoid: high-dose supplements without medical approval.

7. Limit: alcohol; it can worsen BP and sleep. Avoid: binge drinking.

8. Limit: caffeine if you have BP spikes or palpitations. Avoid: OTC decongestants (like pseudoephedrine) without medical clearance if pheochromocytoma is suspected. NCBI

9. If a retina procedure is planned: follow your surgeon’s instructions about fish-oil, vitamin E, or herbals that affect bleeding time.

10. If on belzutifan: maintain iron-rich foods (meat, lentils, leafy greens) and report fatigue; do not self-start iron unless tested for deficiency. FDA Access Data

---

Frequently asked questions

1) Is VHL cancer?
VHL itself is not cancer, but it raises the risk of several tumors, some benign and some malignant (like kidney cancer). Cancer.gov

2) How is VHL inherited?
Autosomal dominant—each child of an affected parent has a 50% chance to inherit the variant. Genetic counseling explains family testing and timing. Cancer.gov

3) Will I definitely get tumors?
Penetrance is high: most carriers develop one or more VHL-related growths by older adulthood, which is why surveillance is crucial. Cancer.gov

4) What is the main pathway driving VHL tumors?
Loss of VHL function stabilizes HIF-α proteins, turning on pro-angiogenic genes (like VEGF). This is why HIF-2α inhibitors, such as belzutifan, help. PMC

5) What is the “3-cm rule” for kidney tumors?
Many centers observe small RCCs and recommend nephron-sparing surgery when the largest tumor reaches ~3 cm, balancing metastasis risk and kidney preservation. American Urological Association

6) Can laser fix all retinal tumors?
Laser and cryotherapy work best for small lesions; larger or peripheral tumors may need different strategies, including PDT, radiation, or vitreoretinal surgery. VHL Alliance

7) Do anti-VEGF eye injections cure retinal hemangioblastomas?
They mainly reduce leakage/exudation and may stabilize vision; tumor control is variable, so they’re often adjuncts to laser/cryotherapy or surgery. Review of OphthalmologyPMC

8) When is radiosurgery used?
For small or surgically difficult brain hemangioblastomas; long-term studies show high local control with low toxicity in selected patients. Oxford Academic

9) How do we make adrenal surgery safe in pheochromocytoma?
By alpha-blockade first (phenoxybenzamine or doxazosin), then adding a beta-blocker if needed; fluids expand blood volume. NCBI

10) What does belzutifan do?
It blocks HIF-2α, shrinking or stabilizing VHL-related tumors so some surgeries can be delayed. Watch for anemia and hypoxia; pregnancy must be avoided. FDA Access Data

11) How long do I take belzutifan?
Usually daily and ongoing until disease progression or side effects require changes. Your team adjusts dose if anemia or hypoxia occurs. FDA Access Data

12) Can VHL be prevented?
The gene change itself cannot be prevented. What can be prevented are complications—through surveillance and timely, tissue-sparing treatments. PubMed

13) What about pregnancy and VHL?
Discuss plans early. Some tumors can grow during pregnancy, and belzutifan must not be used in pregnancy. Care is individualized with high-risk OB. FDA Access Data

14) Where should I get care?
Seek centers with multidisciplinary VHL expertise (urology, neurosurgery, neuro-oncology, retina, ENT, endocrinology, genetics). VHL Alliance lists helpful resources. VHL Alliance

15) What is the outlook today?
With organized surveillance, modern microsurgery/radiosurgery, and targeted therapy like belzutifan, many people live full lives with fewer major surgeries than before. PubMedFDA Access Data

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 24, 2025.

PDF Document For This Disease Conditions References